Short Interest in Aethlon Medical, Inc. (NASDAQ:AEMD) Drops By 52.0%

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 479,400 shares, a decrease of 52.0% from the February 13th total of 998,100 shares. Based on an average daily volume of 3,170,000 shares, the days-to-cover ratio is presently 0.2 days. Currently, 3.4% of the shares of the stock are short sold.

Institutional Investors Weigh In On Aethlon Medical

A number of institutional investors have recently bought and sold shares of AEMD. Boothbay Fund Management LLC acquired a new stake in Aethlon Medical during the fourth quarter worth $186,000. Virtu Financial LLC bought a new position in shares of Aethlon Medical during the fourth quarter valued at $81,000. Sassicaia Capital Advisers LLC bought a new position in shares of Aethlon Medical during the fourth quarter valued at $31,000. Allegiance Financial Group Advisory Services LLC bought a new position in shares of Aethlon Medical during the fourth quarter valued at $26,000. Finally, Renaissance Technologies LLC bought a new position in shares of Aethlon Medical during the fourth quarter valued at $25,000. Institutional investors and hedge funds own 1.99% of the company’s stock.

Wall Street Analysts Forecast Growth

AEMD has been the subject of a number of research analyst reports. StockNews.com started coverage on shares of Aethlon Medical in a report on Wednesday. They issued a “sell” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Aethlon Medical in a report on Monday.

Aethlon Medical Stock Performance

NASDAQ:AEMD opened at $0.42 on Friday. The company has a market capitalization of $6.11 million, a P/E ratio of -0.27 and a beta of 1.80. The stock’s 50 day moving average price is $0.63 and its 200 day moving average price is $0.50. Aethlon Medical has a 52 week low of $0.24 and a 52 week high of $1.85.

Aethlon Medical (NASDAQ:AEMD) last announced its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. As a group, sell-side analysts forecast that Aethlon Medical will post -0.73 earnings per share for the current fiscal year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.